Skip to NavigationSkip to content

Gilead

Gilead to release generic versions of hep C meds over a decade before patent expiry

Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of hepatitis C, Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir), more than a decade before their patents expire.

The company’s hep C portfolio generated $831 million in the second quarter of 2018, and the latter of the pair attracted controversy on its 2014 launch when its $1,150-per-pill price tag was revealed.

Gilead and Galapagos' ankylosing spondylitis drug hits Phase 2 trial goal

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase 2 trial investigating its efficacy in the treatment of moderately to severely active ankylosing spondylitis (AS) in adult patients.

Specifically, the therapy was found to lead to “significantly greater improvements” in AS Disease Activity Score (ASDAS) – the trial’s primary endpoint – after 12 weeks of treatment; the mean change of -1.5 versus -0.6 for placebo, while 76% of patients taking filgotinib achieved an ASAS response of 20 compared to

Novartis' CAR T therapy Kymriah to become available on the NHS

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was revealed that the cancer treatment will be offered to children and young adults up to the age of 25 years old with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

While both Gilead and Novartis’ CAR T therapies were awarded marketing authorisation in the European Union just last week, NICE were quick to reject Gilead’s CAR T therapy Yescarta on the grounds that it was too expensive.

Novartis' Kymriah & Gilead's Yescarta become first EU-approved CAR T therapies

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah (tisagenlecleucel) has been awarded marketing authorisation in the EU for the treatment of blood cancer. Its rival, Gilead/Kite Therapeutics’ Yescarta (axicabtagene ciloleucel) has also been authorised, marking the first approval of its kind in the region.

As CAR-T therapies, both are manufactured from immune cells derived from a specific patient’s body.

Gilead CMO announces departure alongside two new exec appointments

Published on: 17/08/18

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.

Gilead CMO announces departure alongside two new exec appointments

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.

Dr Andrew Cheng will remain at Gilead until 7 September to aid in the transition period.

Gilead's CEO and Chairman to both step down before year's end

Published on: 30/07/18

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the end of the year, ending his run of 28 years at the company. He will remain in the role while the Board of Directors searches for a successor.

Alongside him, it has also been revealed that Chairman Dr John Martin will also be leaving the company. He has said he will vacate his position on the Board when a replacement CEO has been found.

Top Ten most popular articles on Pharmafile.com this week

With the UK in the grip of a record-breaking heatwave, it's hard to focus on much else over here, but it's been another packed week in the pharma industry.

The Brexit farce continues as the UK Government has admitted that the NHS will need to stockpile medicines in the event no deal can be reached with the EU on an exit deal, and Roche and AstraZeneca have followed in Pfizer's footsteps with pledges to pause price hikes until 2019, after the latter firm was chastised over social media by President Donald Trump.

But the most-read story this week is the heart-breaking news th

Gilead's CEO and Chairman to both step down before year's end

Image Credit: Gilead

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the end of the year, ending his run of 28 years at the company. He will remain in the role while the Board of Directors searches for a successor.

Alongside him, it has also been revealed that Chairman Dr John Martin will also be leaving the company. He has said he will vacate his position on the Board when a replacement CEO has been found.

Top Ten most popular articles on Pharmafile.com this week

The first day of June - time for another top ten run-down. It's been a week somewhat characterised by trial failures, terminations, and job cuts, but there have been triumphs too. Perhaps one of the most striking stories this week was the news that a Google AI platform showed the capacity to identify skin cancer with greater accuracy than more than 50 professional dermatologists after it was trained to do so.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches